Clinical characteristics and prognosis analysis of 13 cases of newly diagnosed plasmablastic lymphoma

Bingling Guo, Zhixiong Yang, Chaoyu Wang, Chongling Hu, Jun Li, Xi Quan, lvxiang xu, Tingting Liu, Jing Lv, Qi Qin, Yan Xiong, Junming Liu, Dehong Huang, Ying Xiang, Qiying Li, Y. Nan, Jian Li, Yao LiuResearch Square 2025 · DOI

TL;DR

Plasmablastic lymphoma (PBL) is a rare, highly aggressive cancer that has historically carried a grim prognosis, particularly for patients with HIV. This retrospective study of 13 patients suggests that while PBL remains challenging, modern standardized treatments—including novel agents like bortezomib and stem cell transplants—can significantly extend survival, and surprisingly, HIV status may no longer be a primary driver of poor outcomes.

What Problem Does This Paper Address?

Plasmablastic lymphoma is a "double threat" in oncology: it is both rare and exceptionally malignant. Derived from plasma cells, it often presents in immunodeficient individuals (classically those with HIV) and is notorious for its resistance to standard chemotherapy.

Because it is so rare, there is no globally established "gold standard" for treatment. Historically, the median overall survival was a dismal 15 months. Clinicians face a significant gap in understanding which specific factors (like age, HIV status, or blood markers) actually dictate a patient's chance of survival and whether newer "targeted" drugs are effective when integrated into first-line therapy.

Methods

The researchers conducted a retrospective clinical analysis of 13 newly diagnosed PBL patients treated at Chongqing University Cancer Hospital between 2013 and 2024.

Key technical approaches included:

  • Immunophenotyping: Using markers like CD38, CD138, and MUM-1 to confirm the PBL diagnosis.
  • Survival Analysis: Employing Kaplan-Meier curves and Log-rank tests to compare survival times across different patient subgroups.
  • Risk Factor Identification: Using univariate and multivariate Cox regression models to determine which clinical characteristics (e.g., anemia, gender, IPI score) statistically correlated with shorter life expectancy or disease progression.
  • Treatment Stratification: Comparing traditional chemotherapy (CHOP/EPOCH) against regimens supplemented with "new drugs" (proteasome inhibitors like bortezomib, immunomodulators like lenalidomide, and PD-1 inhibitors) and autologous stem cell transplantation (ASCT).

Datasets

The study relies on a localized clinical dataset of 13 patients from a single center in China. While the sample size is small—a common limitation in rare disease research—the longitudinal data spans over a decade (2013–2024), providing a detailed look at long-term outcomes and treatment evolution.

Key Insights and Ideas

  • The HIV "Neutrality" Finding: Perhaps the most surprising insight is that HIV infection did not significantly impact prognosis. In this cohort, HIV-positive patients fared as well as HIV-negative patients, suggesting that modern standardized care can overcome the historical "AIDS-defining" disadvantage of this cancer.
  • The Timing of Novel Therapies: The study highlights a "window of opportunity." New drugs (bortezomib, lenalidomide) showed clear benefits when used in first-line treatment. However, when these same drugs were used as a third-line "hail mary" for relapsed patients, they were largely ineffective.
  • Predictive Red Flags: The researchers identified two primary biomarkers for poor prognosis:
  • Anemia (Hemoglobin ≤120g/L): A strong predictor of shorter progression-free survival.
  • High IPI Score (3-5): The International Prognostic Index remains a gold standard for predicting both overall and progression-free survival in PBL.
  • The Power of Consolidation: Combining aggressive chemotherapy with Autologous Stem Cell Transplantation (ASCT) appeared to be a key factor in achieving long-term remission.

Key Results

  • Improved Survival: The median Overall Survival (OS) was 33.08 months, and the median Progression-Free Survival (PFS) was 25.62 months. This is a notable improvement over the ~15-month median survival cited in older literature.
  • Treatment Efficacy: 11 out of 13 patients showed a response to first-line treatment (5 Complete Remissions, 6 Partial Remissions).
  • Statistical Significance: Kaplan-Meier analysis confirmed that IPI scores of 3-5, the presence of "B symptoms" (fever, night sweats, weight loss), and male gender were significantly associated with shorter survival times ($P < 0.05$).
  • EBV Association: 69.2% of patients had elevated Epstein-Barr Virus (EBV) DNA in their blood, reinforcing the link between viral infection and the pathogenesis of this lymphoma.

Limitations and Future Work

The primary limitation is the small sample size (n=13), which limits the statistical power of the multivariate analysis. As a retrospective study, it is also subject to selection bias and variations in how patients were treated over the 11-year span.

The authors suggest that while their results are promising, multi-center prospective trials are needed to validate these findings. Specifically, future research should focus on refining the "cocktail" of new drugs (bortezomib + PD-1 inhibitors) to see if chemotherapy-free or reduced-intensity regimens could achieve similar results with less toxicity.

Summary updated

Abstract

<title>Abstract</title> <bold>Objective</bold> To explore the clinical characteristics, treatment, and prognosis of patients with newly diagnosed plasmablastic lymphoma (PBL). <bold>Methods</bold> The clinical data of 13 newly diagnosed PBL patients admitted to Chongqing University Cancer Hospital from January 2013 to June 2024 were retrospectively analyzed. Survival analysis was performed using the Kaplan-Meier survival curve and Log-rank test. Univariate and multivariate Cox regression model analyses were used for analyzing prognostic factors. <bold>Results</bold> ①The number of male and female cases was 10:3. The median age was 52.15 (26-78) years old. Six cases (46.1%) had extranodal organ involvement as the initial symptom, including 3 cases (23.1%) of oral and maxillofacial region. There were 7 cases (53.9%) in Ann-Arbor stage Ⅰ~Ⅱ and 6 cases (46.1%) in stage Ⅳ. Six cases (46.1%) had B symptoms. Two cases (15.3%) had an IPI score ≥3. Nine cases (69.2%) had elevated peripheral blood EB-DNA detection. One case had bone marrow invasion (7.7%), and one case had central nervous system invasion. ②All patients expressed CD38, CD138, and MUM-1. B-cell markers such as PAX-5 and Bcl-6 were occasionally seen. Six cases (46.2%) had positive EBER detection. ③All 13 patients received chemotherapy, and 3 cases received combined radiotherapy. The median follow-up was 48.31 (16-141) months. The median OS was 33.08 (11-79) months, and the median PFS was 25.62 (2-79) months. ④Seven cases received the EPOCH regimen, 6 cases received the CHOP or CHOP-like regimen. Five cases received new drugs in the first-line treatment (3 cases combined with bortezomib, 1 case combined with lenalidomide, and 1 case combined with a PD-1 inhibitor). Three cases received combined local radiotherapy. After first-line treatment, 5 cases had a CR evaluation, 6 cases had a PR evaluation, 1 case had SD, and 1 case had NA. ⑤The best efficacy evaluation: 5 cases had CR, 7 cases had PR, and 1 case had NA. The combination of new drugs and autologous stem cell transplantation (ASCT) in the first-line treatment had obvious benefits, but the use of new drugs such as Lenalidomide and Selinexor in the third-line and above had poor effects. ⑥Kaplan-Meier analysis showed that the overall survival of PBL was significantly related to IPI score 3-5, B symptoms, and male gender (P&lt;0.05). According to univariate COX regression analysis, for newly diagnosed PBL, anemia (≤120g/L) and IPI score 3-5 were factors for poor prognosis of PFS. IPI score 3-5 was a factor for poor prognosis of OS. Combined HIV infection had no significant impact on prognosis. <bold>Conclusions</bold> For PBL treated through standardized treatment, the impact of HIV infection on prognosis can be overcome. At initial diagnosis, anemia (≤120g/L) and IPI score 3-5 are factors for poor prognosis of PFS in PBL. IPI score 3-5 is a factor for poor prognosis of OS. The first-line treatment choice of combining new drugs (Bortezomib, Lenalidomide, PD-1 inhibitor) and ASCT is expected to improve the prognosis of PBL.
BibTeX
@inproceedings{guo2025clinical,
  author = {Bingling Guo and Zhixiong Yang and Chaoyu Wang and Chongling Hu and Jun Li and Xi Quan and lvxiang xu and Tingting Liu and Jing Lv and Qi Qin and Yan Xiong and Junming Liu and Dehong Huang and Ying Xiang and Qiying Li and Y. Nan and Jian Li and Yao Liu},
  title = {{Clinical characteristics and prognosis analysis of 13 cases of newly diagnosed plasmablastic lymphoma}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-5917684/v1},
}
Figure